Developing preclinical and clinical study designs
• Experience in developing both preclinical and early phase comparative studies to maximize the potential of similarity in clinical phase including employing modeling and simulation techniques
• The experience to design comparability studies to assess the similarity between biosimilars and the marketed reference compounds
• Expert knowledge of pharmacodynamic (PD) markers that can serve as surrogate endpoints for biosimilar clinical studies
Return to the overview.